Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.
Fiche publication
Date publication
novembre 2020
Journal
Annals of the rheumatic diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas, Pr GOTTENBERG Jacques-Eric, Pr MARTIN Thierry
Tous les auteurs :
Felten R, Devauchelle-Pensec V, Seror R, Duffau P, Saadoun D, Hachulla E, Pierre Yves H, Salliot C, Perdriger A, Morel J, Mékinian A, Vittecoq O, Berthelot JM, Dernis E, Le Guern V, Dieudé P, Larroche C, Richez C, Martin T, Zarnitsky C, Blaison G, Kieffer P, Maurier F, Dellal A, Rist S, Andres E, Contis A, Chatelus E, Sordet C, Sibilia J, Arnold C, Tawk MY, Aberkane O, Holterbach L, Cacoub P, Saraux A, Mariette X, Meyer N, Gottenberg JE
Lien Pubmed
Résumé
No immunomodulatory drug has been approved for primary Sjögren's syndrome, a systemic autoimmune disease affecting 0.1% of the population. To demonstrate the efficacy of targeting interleukin 6 receptor in patients with Sjögren's syndrome-related systemic complications.
Mots clés
Sjogren's syndrome, biological therapy, cytokines
Référence
Ann Rheum Dis. 2020 Nov 18;: